Company: CERO
Filing Date: 2025-01-07
Form Type: 424B3
Source: 0001213900-25-001661
Chunk: 4

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-07
Form: 424B3
Chunk 4
---

(Former name or former address, if changed since last report)</div>

Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |

| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |

| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |

| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class                                                    |     | Trading Symbol(s) |     | Name of each exchange on 
 which registered         |
| Common Stock, par value $0.0001 per share                              |     | CERO              |     | NASDAQ Global Market     |
| Warrants, each whole warrant exercisable for one share of common stock |     | CEROW             |     | NASDAQ Capital Market    |

Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

Emerging growth company ☒

If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

On January 6, 2025, CERo
Therapeutics Holdings, Inc. (the “Company”) filed an amendment (the “Certificate of Amendment”) to its Second
Amended and Restated Certificate of Incorporation, as amended and/or restated from time to time, to effectuate a reverse stock split of
the Company’s issued and outstanding shares of common stock, par value $0.0001 per share (the “Common Stock”).

As previously disclosed,
at its Autumn 2024 Special Meeting of Stock